Proton-beam therapy for tumors of the CNS

Expert Review of Neurotherapeutics

Volumn 10, Issue 2, 2010, Pages 319-330

  Gridley, Daila S ^a   Grover, Ryan S ^a   Loredo, Lilia N ^a   Wroe, Andrew J ^a   Slater, Jerry D ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; CNS; Craniopharyngioma; Ependymoma; Glioblastoma; Glioma; Ionizing radiation; Medulloblastoma; Multiforme; Particle radiotherapy; Pituitary adenoma; Radiosurgery

Indexed keywords

ACOUSTIC NEURINOMA; ASTROCYTOMA; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; CRANIOPHARYNGIOMA; DISEASE COURSE; DRUG MEGADOSE; EPENDYMOMA; FATIGUE; GERM CELL TUMOR; GLIA CELL; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; HYPOPHYSIS ADENOMA; INTENSITY MODULATED RADIATION THERAPY; MALIGNANT NEURILEMOMA; MEDULLOBLASTOMA; MENINGIOMA; MENTAL DETERIORATION; METASTASIS; NEURILEMOMA; OLIGODENDROGLIOMA; ONCOLOGY; OPTIC NERVE GLIOMA; PINEAL BODY TUMOR; PROTON THERAPY; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; TOXICITY;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; PROTONS; RADIATION ONCOLOGY; RADIOTHERAPY;

EID: 76249120357     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.150     Document Type: Review

References (77)

1. Slater JD. Clinical applications of proton radiation treatment at Loma Linda University: review of a fifteen-year experience. Technol. Cancer Res. Treat. 5(2), 81-89 (2006). •• Excellent article that provides an overview of proton radiotherapy at the institution with the greatest experience over nearly 20 years in treating patients.
2. Slater, JM. Considerations in identifying optimal particles for radiation medicine. Technol. Cancer Res. Treat. 5(2), 73-79 (2006).
3. Slater JM. Selecting the optimal particle for radiation therapy. Technol. Cancer Res. Treat. 6(4), 35-39 (2007). •• Comprehensive review that provides a rationale for selecting protons for heavy-charged-particle radiotherapy.
4. Bonnett DE. Current developments in proton therapy: a review. Phys. Med. Biol. 38, 1371-1392 (1993).
5. Suit H, Goldberg S, Niemierko A et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 42(8), 800-808 (2003).
6. Douw L, Klein M, Fagel, SS et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 8(9), 810-818 (2009).
7. Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin. Oncol. 31(5), 702-713 (2004).
8. Brown PD, Buckner JC, O'Fallon JR et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J. Clin. Oncol. 21(13), 2519-2524 (2003).
9. Laack NN, Brown PD, Ivnik RJ et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Center Cancer Treatment Group prospective study. Int. J. Radiat. Oncol. Biol. Phys. 63(4), 1175-1183 (2005).
10. Monje M. Cranial radiation therapy and damage to hippocampal neurogenesis. Dev. Disabil. Res. Rev. 14(3), 238-242 (2008).
11. Monje ML, Vogel H, Masek M et al. Impaired human hipocampal neurogenesis after treatment for central nervous system malignancies. Ann. Neurol. 62(5), 515-520 (2007).
12. Abayomi OK, Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta Oncol. 41(4), 346-351 (2002).
13. Mizumatsu S, Monje ML, Morhardt DR et al. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. 63(14), 4021-4027 (2003).
14. Merchant TE, Hua CH, Shukla H et al. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr. Blood Cancer 51(1), 110-117 (2008).
15. Palm A, Johansson KA. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors. Acta Oncol. 46(4), 462-473 (2007).
16. Suit H, Goldberg S, Niemierko A et al. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat. Res. 167(1), 12-42 (2007).
17. Miralbell R, Lomax A, Cella L et al. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int. J. Radiat. Oncol. Biol. Phys. 54(3), 824-829 (2002).
18. Newhauser WD, Fontenot JD, Mahajan A et al. The risk of developing a second cancer after receiving craniospinal proton radiation. Phys. Med. Biol. 54(8), 2277-2291 (2009).
19. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65(1), 1-7 (2006).
20. Gottschalk B. Neutron dose in scattered and scanned proton beams: in regard to Eric J. Hall (Int. J. Radiat. Oncol. Biol. Phys. 65, 1-7, 2006). Int. J. Radiat. Oncol. Biol. Phys. 66, 1594 (2006).
21. Paganetti H, Bortfeld T, Delaney TF. Neutron dose in proton radiation therapy: In regard to Eric J. Hall (Int. J. Radiat. Oncol. Biol. Phys. 65, 1-7, 2006). Int. J. Radiat. Oncol. Biol. Phys. 66, 1594-1595 (2006).
22. Jarlskog C, Lee C, Bolch WE et al. Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms. Physics Med. Biol. 53(3), 693 (2008).
23. Zacharatou-Jarlskog C, Lee C, Jiang H et al. Monte Carlo simulations using whole-body pediatric and adult phantoms as virtual patients to assess secondary organ doses in proton radiation therapy. Med. Phys. 33(6), 2123 (2006).
24. Wroe A, Rosenfeld A, Schulte R. Out-of-field dose equivalents delivered by proton therapy of prostate cancer. Med. Phys. 34, 3449-3456 (2007).
25. Wroe A, Clasie B, Kooy H. Out-of-field dose equivalents delivered by passively scattered therapeutic proton beams for clinically relevant field configurations. Int. J. Rad. Onc. Biol. Phys. 73(1), 306-313 (2009).
26. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 58(2), 71-96 (2009).
27. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr. Cancer Drug Targets 9(3), 381-390 (2009).
28. van den Bent MJ, Afra D, de Witte O et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Lancet 366(9490), 985-990 (2005). Erratum in: Lancet 367(9525), 1818 (2006).
29. Schomas DA, Laack NN, Rao RD et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol. 11(4), 437-445 (2009).
30. Walker M, Green S, Byar D et al. Randomized comparisons of radiotherapy and nitrosurias for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323-1329 (1980).
31. Lee S, Fraass B, Herbort K et al. Patterns of failure following high dose 3-D conformal radiotherapy for high grade astrocytomas: a quantitative dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. 43, 79-88 (1999).
32. Chan J, Lee, S, Benedick F et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J. Clin. Oncol. 20(6), 1635-1642 (2002).
33. Fitzek M, Thornton A, Rabinov J et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a Phase II prospective trial. J. Neurosurg. 91, 251-260 (1999).
34. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
35. Mirimanoff R, Mason W, Van den Bent M et al. Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus RT alone. Int. J. Radiat. Oncol. Biol. Phys. 69(3), S2-S2 (2007).
36. Glas M, Happold C, Rieger J et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. Clin. Oncol. 27(8), 1257-1261 (2009).
37. Ronson BB, Schulte RW, Han KP et al. Fractionated proton beam irradiation of pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 425-434 (2006).
38. Luu QT, Loredo LN, Archambeau JO et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: Preliminary report. Cancer J. 12, 155-159 (2006).
39. Fitzek MM, Linggood RM, Adams J et al. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int. J. Radiat. Oncol. Biol. Phys. 64(5), 1348-1354 (2006).
40. Winkfield KM, Linsenmeier C, Yock TI et al. Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 73(3), 716-721 (2009).
41. Munzenrider JE. Proton therapy for uveal melanomas and other eye lesions. Strahlenther. Onkol. 175(S2), 68-73 (1999).
42. Zografos L, Ducrey N, Beati D et al. Metastatic melanoma in the eye and orbit. Ophthalmology 110(11), 2245-2256 (2003).
43. Egger E, Zografos L, Schalenbourg A. Eye retention after proton beam radiotherapy for uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 55(4), 867-880 (2003).
44. Egger E, Schalenbourg A, Zografos L. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 51(1), 138-147 (2001).
45. Purdy JA. Dose to normal tissue outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys. 95(5), 666-676 (2008).
46. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of proton therapy. Cancer Treat. Rev. 35, 79-96 (2009).
47. Lin R, Hug E, Schaefer R et al. Conformal proton radiation therapy of the posterior fossa: a study comparing protons with three-dimensional planned photons in limiting dose to auditory structures. Int. J. Radiat. Oncol. Biol. Phys. 48(4), 1219-1226 (2000).
48. Yu GE, Loredo LN, Yonemoto LT et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. CancerJ. 10(6), 386-390 (2004).
49. Timmermann B, Lomax AJ, Nobile L et al. Novel technique of craniospinal axis proton therapy with the spot-scanning system: avoidance of patching multiple fields and optimized ventral dose distribution. Strahlenther. Onkol. 183(12), 685-688 (2007).
50. Krejcarek, SC, Grant, PE, Henson, JW et al. Physiologic and radiographic evidence of the distal edge of the proton beam in craniospinal irradiation. J. Radiat. Oncol. Biol. Phys. 68(3), 646-649 (2007).
51. Rutz HP, Weber DC, Goitein G et al. Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcome in children and adolescents: initial experience at Paul Scherrer Institute. Int. J. Radiat. Oncol. Biol. Phys. 71(1), 220-225 (2008).
52. MacDonald SM, Safai S, Trofimov A et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int. J. Radiat. Oncol. Biol. Phys. 71(4), 979-986 (2008).
53. St Clair WH, Adams JA, Bues M et al. Advantage of protons compared to conventional x-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 727-734 (2004).
54. Jain KK. Future prospects for the cure of brain cancer. Technol. Cancer Res. Treat. 5(3), 183-184 (2006).
55. Gridley DS, Miller GM, Luo X et al. Proton radiation and TNF-α/Bax gene therapy for orthotopic C6 brain tumor in Wistar rats. Technol. Cancer Res. Treat. 3(2), 217-227 (2004).
56. Brisman JL, Cosgrove GR, Thornton AF et al. Hyperacute neuropathological findings after proton beam radiosurgery of the rat hippocampus. Neurosurgery 56(6), 1330-1337 (2005).
57. Mao XW, Crapo JD, Mekonnen T et al. Radioprotective effect of a metalloporphyrin compound in rat eye model. Curr. Eye Res. 34, 62-72 (2009).
58. Gridley DS, Makinde AY, Luo X et al. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res. 27(5A), 3101-3109 (2007).
59. Makinde AY, Luo-Owen X, Rizvi A et al. Effect of a metalloprorphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. Anticancer Res. 29(1), 107-118 (2009).
60. Ohnishi K, Ohnishi T. The biological effects of space radiation during long stays in space. Biol. Sci. Space 18(4), 201-205 (2004).
61. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience 158(3), 1122-1132 (2009).
62. Gridley DS, Rizvi A, Luo-Owen X et al. Variable hematopoietic responses to acute photons, protons and simulated solar particle event protons. InVivo 22, 159-169 (2008).
63. + T cell gene expression. Int. J. Radiat. Biol. 85(3), 250-261 (2009).
64. Gridley DS, Coutrakon GB, Rizvi A et al. Low dose photons modify liver response to simulated solar particle event protons. Radiat. Res. 169, 280-287 (2008).
65. Fan JB, Mascia AE, Hsi W-C et al. Clinical characterization of a proton beam continuous uniform scanning system with dose layer stacking. Med. Phys. 35(11), 4945-4954 (2008).
66. Oelfke U, Bortfeld T. Optimization of physical dose distributions with Hadron beams: comparing photon IMRT with IMPT. Technol. Cancer Res. Treat. 2(5), 401-412 (2003).
67. Widesott L, Pierelli A, Fiorino C et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 589-596 (2008).
68. Trofimov A, Bortfeld T. Optimization of beam parameters and treatment planning for intensity modulated proton therapy. Technol. Cancer Res. Treat. 2(5), 437-444 (2003).
69. Rutz HP, Weber DC, Sugahara S et al. Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 512-520 (2007).
70. Weber DC, Lomax AJ, Rutz HP et al. Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother. Oncol. 71, 251-258 (2004).
71. Weber DC, Rutz HP, Pedroni ES et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcomaof the skull base: the Paul Scherrer Institut experience. Int. J. Radiat. Oncol. Biol. Phys. 63(2), 401-409 (2005).
72. Nieder C, Mehta MP, Jalali R. Combined radio- and chemotherapy of brain tumours in adult patients. Clin. Oncol. (R. Coll. Radiol.) 21(7), 515-524 (2009).
73. Noda SE, El-Jawahri A, Patel D et al. Molecular advances of brain tumor in radiation oncology. Semin. Radiat. Oncol. 19(3), 171-178 (2009).
74. Mercer RW, Tyler MA, Ulasov IV et al. Targeted therapies for malignant glioma: progress and potential. BioDrugs 23(1), 25-35 (2009).
75. Tu LC, Foltz G, Lin E et al. Targeting stem cells - clinical implications for cancer therapy. Curr. Stem Cell Res. Ther. 4(2), 147-153 (2009).
76. 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 2008www.astro.org
77. Proton Therapy Co-operative Grouphttp://ptcog.web.psi.ch